BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 17564791)

  • 1. Immunoexpression of endoglin in brain metastasis secondary to malignant melanoma: evaluation of angiogenesis and comparison with brain metastasis secondary to breast and lung carcinomas.
    Salgado KB; Toscani NV; Silva LL; Hilbig A; Barbosa-Coutinho LM
    Clin Exp Metastasis; 2007; 24(6):403-10. PubMed ID: 17564791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of angiogenesis evaluated by CD105 expression compared to CD31 in 905 breast carcinomas: correlation with long-term patient outcome.
    Dales JP; Garcia S; Andrac L; Carpentier S; Ramuz O; Lavaut MN; Allasia C; Bonnier P; Charpin C
    Int J Oncol; 2004 May; 24(5):1197-204. PubMed ID: 15067342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of neovasculature in uveal melanoma by targeting the TGFbeta-binding receptor endoglin: is there prognostic relevance of proliferating endothelium?
    Ziemssen F; Wegner R; Wegner J; Tatar O; Süsskind D; Gelisken F; Rohrbach M; Bartz-Schmidt KU; Grisanti S
    Graefes Arch Clin Exp Ophthalmol; 2006 Sep; 244(9):1124-31. PubMed ID: 16523306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Relevance of Endoglin (CD105) VEGF and p53 with invasion metastasis and prognosis of laryngeal carcinoma].
    Li Q; Zhang B; Peng P
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2007 Dec; 21(24):1114-7. PubMed ID: 18330257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endoglin (CD105) expression and angiogenesis status in small cell lung cancer.
    Takase Y; Kai K; Masuda M; Akashi M; Tokunaga O
    Pathol Res Pract; 2010 Nov; 206(11):725-30. PubMed ID: 20619547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transforming growth factor-beta binding receptor endoglin (CD105) expression in esophageal cancer and in adjacent nontumorous esophagus as prognostic predictor of recurrence.
    Bellone G; Solerio D; Chiusa L; Brondino G; Carbone A; Prati A; Scirelli T; Camandona M; Palestro G; Dei Poli M
    Ann Surg Oncol; 2007 Nov; 14(11):3232-42. PubMed ID: 17682823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of CD105, α-SMA and VEGF expression in gastric carcinomas.
    Grigore D; Simionescu CE; Stepan A; Mărgăritescu C; Bălăşoiu M; Georgescu CC; Cernea D; Dumitrescu D
    Rom J Morphol Embryol; 2013; 54(3 Suppl):701-7. PubMed ID: 24322015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The immunohistochemical expression of CD105 is a marker for high metastatic risk and worse prognosis in breast cancers].
    Charpin-Taranger C; Dales JP; Garcia S; Andrac-Meyer L; Ramuz O; Carpentier-Meunier S; Bonnier P
    Bull Acad Natl Med; 2003; 187(6):1129-45; discussion 1145-6. PubMed ID: 14978873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunocytochemical detection of endoglin is indicative of angiogenesis in malignant melanoma.
    Bodey B; Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1998; 18(4A):2701-10. PubMed ID: 9703932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endoglin (CD105) expression in angiogenesis of primary hepatocellular carcinomas: analysis using tissue microarrays and comparisons with CD34 and VEGF.
    Yao Y; Pan Y; Chen J; Sun X; Qiu Y; Ding Y
    Ann Clin Lab Sci; 2007; 37(1):39-48. PubMed ID: 17311868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Morphometric and immunohistochemical study of angiogenic marker expressions in invasive ductal carcinoma of human breast.
    Safwat MD; Habib F; Elayat A; Oweiss N; Reffat S; Algaidi S
    Folia Morphol (Warsz); 2009 Aug; 68(3):144-55. PubMed ID: 19722158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody.
    Tanaka F; Otake Y; Yanagihara K; Kawano Y; Miyahara R; Li M; Yamada T; Hanaoka N; Inui K; Wada H
    Clin Cancer Res; 2001 Nov; 7(11):3410-5. PubMed ID: 11705856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endoglin is a better marker than CD31 in evaluation of angiogenesis in glioblastoma.
    Behrem S; Zarkovic K; Eskinja N; Jonjic N
    Croat Med J; 2005 Jun; 46(3):417-22. PubMed ID: 15861521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor angiogenesis in predicting the survival of patients with stage I lung cancer.
    Medetoglu B; Gunluoglu MZ; Demir A; Melek H; Buyukpinarbasili N; Fener N; Dincer SI
    J Thorac Cardiovasc Surg; 2010 Nov; 140(5):996-1000. PubMed ID: 20708755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathologic significance of CD105 expression in squamous cell carcinoma of the hypopharynx.
    Chien CY; Su CY; Hwang CF; Chuang HC; Hsiao YC; Wu SL; Huang CC
    Head Neck; 2006 May; 28(5):441-6. PubMed ID: 16320363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical evaluation of the microvascular density through the expression of TGF-beta (CD 105/endoglin) and CD 34 receptors and expression of the vascular endothelial growth factor (VEGF) in oligodendrogliomas.
    Netto GC; Bleil CB; Hilbig A; Coutinho LM
    Neuropathology; 2008 Feb; 28(1):17-23. PubMed ID: 18181830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relationship between CD105 and angiogenesis and biological behaviors in squamous carcinoma of larynx].
    Gu X; Xu Y; Wu H; Xu X
    Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2006 Feb; 20(3):125-8. PubMed ID: 16646406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD105 (Endoglin) expression in breast carcinoma effusions is a marker of poor survival.
    Davidson B; Stavnes HT; Førsund M; Berner A; Staff AC
    Breast; 2010 Dec; 19(6):493-8. PubMed ID: 21078485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic angiogenic markers (endoglin, VEGF, CD31) and tumor cell proliferation (Ki67) for gastrointestinal stromal tumors.
    Basilio-de-Oliveira RP; Pannain VL
    World J Gastroenterol; 2015 Jun; 21(22):6924-30. PubMed ID: 26078569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microvessel density assessment in benign and malignant endometrial changes.
    Czekierdowski A; Czekierdowska S; Czuba B; Cnota W; Sodowski K; Kotarski J; Zwirska-Korczala K
    J Physiol Pharmacol; 2008 Sep; 59 Suppl 4():45-51. PubMed ID: 18955753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.